NEW YORK, NY / ACCESSWIRE / November 27, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Raytheon Technologies Corporation (NYSE:RTX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/raytheon-technologies-corporation-loss-submission-form?prid=11256&wire=1
Lead Plaintiff Deadline: December 29, 2020
Class Period: February 10, 2016 - October 27, 2020
Allegations against RTX include that: (1) Raytheon had inadequate disclosure controls and procedures and inadequate internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon Company's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Biogen Inc. (NASDAQ:BIIB)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/biogen-inc-loss-submission-form?prid=11256&wire=1
Lead Plaintiff Deadline: January 12, 2021
Class Period: October 22, 2019 - November 6, 2019
Allegations against BIIB include that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Joyy Inc. (NASDAQ:YY)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/joyy-inc-loss-submission-form?prid=11256&wire=1
Lead Plaintiff Deadline: January 19, 2021
Class Period: April 28, 2016 - November 18, 2020
Allegations against YY include that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong